PT766668E - Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes - Google Patents

Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes

Info

Publication number
PT766668E
PT766668E PT95918278T PT95918278T PT766668E PT 766668 E PT766668 E PT 766668E PT 95918278 T PT95918278 T PT 95918278T PT 95918278 T PT95918278 T PT 95918278T PT 766668 E PT766668 E PT 766668E
Authority
PT
Portugal
Prior art keywords
piperidine
derivatives
processes
pseudomorphes
polymorphes
Prior art date
Application number
PT95918278T
Other languages
English (en)
Inventor
Daniel R Henton
Frederick J Mccarty
Susan I Tripp
Jill E Dewitt
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT766668(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PT766668E publication Critical patent/PT766668E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
PT95918278T 1994-05-18 1995-04-28 Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes PT766668E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11

Publications (1)

Publication Number Publication Date
PT766668E true PT766668E (pt) 2002-11-29

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95918278T PT766668E (pt) 1994-05-18 1995-04-28 Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes

Country Status (18)

Country Link
US (12) US20010014741A1 (pt)
EP (3) EP0766668B1 (pt)
JP (7) JPH10500134A (pt)
CN (3) CN1907967B (pt)
AT (1) ATE220667T1 (pt)
AU (1) AU693892B2 (pt)
CA (3) CA2189007C (pt)
DE (1) DE69527429T2 (pt)
DK (1) DK0766668T3 (pt)
ES (1) ES2176329T3 (pt)
FI (1) FI964565A (pt)
HK (2) HK1098467A1 (pt)
HU (1) HU227676B1 (pt)
IL (3) IL134917A (pt)
MX (1) MX9605613A (pt)
NO (1) NO315319B1 (pt)
PT (1) PT766668E (pt)
WO (1) WO1995031437A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
CA2189007C (en) 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
ES2181868T3 (es) 1995-02-28 2003-03-01 Aventis Pharma Inc Composicion farmaceutica para compuestos de piperidinoalcanol.
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
IN191492B (pt) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
EE200400010A (et) * 2001-06-18 2004-02-16 Dr. Reddy's Laboratories Ltd. 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid
PT1414453E (pt) * 2001-07-31 2008-05-29 Texcontor Ets Polimorfo de cloridrato de fexofenadina
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
JP2005532356A (ja) 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
EP1567533B1 (en) 2003-07-03 2009-03-11 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
JP2009543780A (ja) * 2006-07-11 2009-12-10 ミューチュアル ファーマシューティカル カンパニー，インク． 制御放出製剤およびキット
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
EP2496077B1 (en) 2009-11-06 2014-08-20 Basf Se Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
IT1400965B1 (it) 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
BE794598A (fr) * 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US3965257A (en) * 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) * 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (pt) * 1991-04-08 1993-01-11 Green Cross Corp
CA2117892C (en) * 1992-04-10 2001-12-18 Chi-Hsin R. King 4-diphenylmethyl piperidine derivatives and process for their preparation
US5631375A (en) 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
CA2134211C (en) * 1992-05-11 1999-06-29 James K. Woodward Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
EP0701443B2 (en) * 1992-08-03 2000-11-22 Sepracor, Inc. Terfenadine metabolites and their optically pure isomers for treating allergic disorders
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
DE69434696T2 (de) 1993-06-24 2006-11-16 Amr Technology, Inc. Verfahren zur Herstellung von Verbindungen geeignet als Zwischenprodukte
CA2254506C (en) 1993-06-24 2000-11-28 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
DE69431954T2 (de) 1993-06-25 2003-11-06 Merrell Pharmaceuticals Inc., Cincinnati Neue zwischenprodukte für die herstellung von antihistaminschen 4-diphenylmethyl/diphenylmethoxypiperidin-derivaten
CA2189007C (en) 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US5576610A (en) * 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
IL134770A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
ES2181868T3 (es) * 1995-02-28 2003-03-01 Aventis Pharma Inc Composicion farmaceutica para compuestos de piperidinoalcanol.
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
JP2002316978A (ja) 2002-10-31
IL113747A0 (en) 1995-08-31
US20030045721A1 (en) 2003-03-06
CA2189007C (en) 2004-03-02
US20020193603A1 (en) 2002-12-19
US20020193601A1 (en) 2002-12-19
US20080167469A1 (en) 2008-07-10
US7138524B2 (en) 2006-11-21
AU693892B2 (en) 1998-07-09
FI964565A0 (fi) 1996-11-14
JPH10500134A (ja) 1998-01-06
DK0766668T3 (da) 2002-10-28
CA2585705A1 (en) 1995-11-23
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23
IL134917A (en) 2001-07-24
CN1623985A (zh) 2005-06-08
EP0766668A1 (en) 1997-04-09
US20070021461A1 (en) 2007-01-25
ES2176329T3 (es) 2002-12-01
AU2426595A (en) 1995-12-05
ATE220667T1 (de) 2002-08-15
US20010025106A1 (en) 2001-09-27
HK1137742A1 (en) 2010-08-06
JP4503909B2 (ja) 2010-07-14
CA2189007A1 (en) 1995-11-23
US20010012896A1 (en) 2001-08-09
HUT76134A (en) 1997-06-30
IL134917A0 (en) 2001-05-20
CN1148849A (zh) 1997-04-30
HU9603167D0 (en) 1997-01-28
US20010014741A1 (en) 2001-08-16
US7662835B2 (en) 2010-02-16
HK1098467A1 (en) 2007-07-20
CN1907967B (zh) 2012-07-04
FI964565A (fi) 1996-11-14
JP4503908B2 (ja) 2010-07-14
MX9605613A (es) 1998-05-31
JP2002255936A (ja) 2002-09-11
WO1995031437A1 (en) 1995-11-23
EP0766668B1 (en) 2002-07-17
US7135571B2 (en) 2006-11-14
CA2585705C (en) 2012-04-17
US20080167471A1 (en) 2008-07-10
HU227676B1 (en) 2011-11-28
JP2010120969A (ja) 2010-06-03
JP4503907B2 (ja) 2010-07-14
DE69527429T2 (de) 2003-03-20
CA2449419C (en) 2011-09-06
NO964859L (no) 1996-11-15
US20020193600A1 (en) 2002-12-19
DE69527429D1 (de) 2002-08-22
EP1178041A1 (en) 2002-02-06
NO315319B1 (no) 2003-08-18
JP2002255935A (ja) 2002-09-11
NO964859D0 (no) 1996-11-15
CA2449419A1 (en) 1995-11-23
US20040014976A1 (en) 2004-01-22
US20070021462A1 (en) 2007-01-25
US7666881B2 (en) 2010-02-23
IL113747A (en) 2001-05-20
CN1907967A (zh) 2007-02-07
JP2002308850A (ja) 2002-10-23

Similar Documents

Publication Publication Date Title
PT766668E (pt) Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes
MX9304649A (es) Procedimiento para producir 7-(sustituido)-9-[glicilo sustituido]-6-desmetil-6-desoxitetraciclinas.
NO933445L (no) Heterocyklisk-cykliske amin-derivater
SE9600406D0 (sv) Novel coompounds
DE69401817D1 (de) Verbesserungen zum herstellen von glasartigem silika
DK55784D0 (da) Xylanderivater og fremgangsmaade til fremstilling deraf samt midler indeholdende xylanderivaterne med antithrombose- og hypolipidaemisk virkning
PT956286E (pt) Sintese de terfenadina e derivados
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
PT97796A (pt) Processo para a preparacao de piperidinas substituidas
ATE123024T1 (de) 4-aminopyridinderivate.
NO20000423D0 (no) Tiazolobenzoheterocykler, deres fremstilling samt medikamenter inneholdende forbindelsene
AR004279A1 (es) Procedimientos para preparar 3-(1-piperazinil)-1,2-benzoisotiazol
ATE258926T1 (de) Verfahren zur herstellung von ranitidin
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
DE59002172D1 (de) Neue 1,3-oxazine.
BR9610392A (pt) Processo para a preparação de derivados de rodanina substituídos com benzila
SE9503757D0 (sv) Process for the production of ranitidine